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Objectives This study sought to investigate quantitative and homogeneity differential echogenicity
changes of the ABSORB scaffold (1.1) during the ﬁrst year after implantation.
Background The imaging of the ABSORB bioresorbable vascular scaffold degradation by intra-
ascular ultrasound (IVUS) has previously demonstrated diminishing gray-level intensity of the
truts over time that can be evaluated by IVUS-based differential echogenicity. The ﬁrst genera-
ion of ABSORB (1.0) showed a 50% reduction in hyperechogenicity at 6 months and restoration
f the pre-ABSORB implantation values at 2 years. The second generation of ABSORB (1.1), in-
estigated in the ABSORB B trial, was modiﬁed to prolong the duration of luminal scaffolding.
ethods A total of 63 patients were examined by IVUS immediately post-implantation and at
-month (Cohort B1, n  28) or 12-month (Cohort B2, n  35) follow-up. IVUS-based tissue compo-
sition analysis software was used to quantify changes in hyperechogenicity over time in the scaf-
folded regions. Relative changes in hyperechogenicity were calculated as: 100  (% hyperechoge-
nicity at follow-up  % hyperechogenicity at baseline)/% hyperechogenicity at baseline.
Results At 6- and 12-month follow-up, there was a 15% (from 22.58  9.77% to 17.42  6.69%,
p  0.001) and 20% (from 23.51  8.57% to 18.25  7.19%, p  0.001) reduction in hyperechoge-
nicity, respectively, compared with post-implantation values. No difference in hyperechogenicity
changes were observed between the proximal, medial, or distal part of the scaffolded segment.
Conclusions Quantitative differential echogenicity changes of the ABSORB scaffold (1.1) during the ﬁrst
12 months after implantation are lower compared with those previously observed with its ﬁrst genera-
tion (1.0), conﬁrming the value of the manufacturing changes and suggesting a slower degradation rate
of the scaffold. (J Am Coll Cardiol Intv 2011;4:1281–9) © 2011 by the American College of Cardiology
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1282Bioresorbable everolimus-eluting vascular scaffolds (ABSORB,
Abbott Vascular, Santa Clara, California) are a novel approach
for treating coronary disease in that they provide transient
vessel support with drug delivery capability, but without the
long-term limitations of metallic stents (1–5). Monitoring the
n vivo bioresorption represents a challenge because the infor-
ation can only be derived indirectly. However, evaluation of
egradation and bioresorption of the ABSORB scaffold at
ifferent time points is important in order to relate it to
ther relevant clinical parameters, such as late changes in
caffold geometry and restoration of vasomotor function (6).
Intravascular ultrasound (IVUS)-derived quantitative echoge-
icity has previously been shown to be valuable to monitor the
egradation and bioresorption processes of the scaffold.
revious benchwork showed that degradation of polymers
esults in different acoustical properties of the material, and
ith respect to the in vivo ABSORB scaffold degradation
rocess, this is detected by IVUS as diminishing gray-level
ntensities of the struts over time (7,8).
The first-generation ABSORB scaffold (1.0), tested in
he ABSORB Cohort A trial, showed a reduction in
VUS-derived hyperechogenicity from 20.9% at post-
bioresorbable vascular scaffold
implantation to 10% at 6 months
and to 6.0% at 2 years, the latter
of which was close to the pre-
ABSORB implantation value of
the scaffolded segment (9). This
reduction in hyperechogenicity
was accompanied by a signifi-
cant reduction in scaffold area
during the first 6 months and
estoration of vasomotor function at 2 years (6,8,10,11).
The second generation of the ABSORB scaffold (1.1) was
odified to prolong the mechanical integrity of the device,
ith the aim of reducing the change in scaffold area over time,
specially in the early phase: this is currently being evaluated in
he ABSORB Cohort B trial (12,13). Of note is that these
nhancements resulted in the absence of the scaffold area
hanges at 6-month follow-up that were previously observed
ith the first generation of ABSORB (9,14).
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and Acronyms
IVUS  intravascular
ultrasound
PDLLA  amorphous
oly(D,L-lactide)
PLLA  semicrystalline
poly(L-lactide)served as consultant/advisory board member for Abbott, Adamed, AstraZeneca,The objective of this study is to investigate the amount
nd homogeneity of the changes in IVUS-derived hyper-
chogenicity of the ABSORB scaffold (1.1) from post-
mplantation to 6- and 12-month follow-up.
ethods
Study population. The ABSORB Cohort B trial enrolled
patients older than 18 years of age with a diagnosis of
stable, unstable, or silent ischemia. The trial was subdi-
vided into 2 subgroups of patients: the first group
(Cohort B1) with invasive imaging with quantitative
coronary angiography, IVUS, IVUS–virtual histology,
and optical coherence tomography at 6- and 24-month
follow-up; the second group (Cohort B2) with the same
invasive imaging but at different follow-up intervals,
namely 12 and 36 months (9). All lesions were de novo,
in a native coronary artery with a reference vessel diam-
eter of 3.0 mm, with a percentage diameter stenosis
50% and 100%, and a Thrombolysis In Myocardial
nfarction flow grade of 1, and were treated with
mplantation of an ABSORB scaffold 1.1 (3.0  18 mm).
ajor exclusion criteria were patients with an acute
yocardial infarction, with unstable arrhythmias, or with
left ventricular ejection fraction 30%, restenotic
esions, lesions located in the left main coronary artery,
esions involving a side branch 2 mm in diameter, and
he presence of thrombus or other clinically significant
tenoses in the target vessel. The ethics committee at
ach participating institution approved the trial, and each
atient gave written informed consent before inclusion.
In the present study, all patients from Cohort B1 and B2
f the ABSORB trial who underwent paired IVUS studies
ost-implantation and at 6- or 12-month follow-up were
nalyzed.
Scaffold design. The ABSORB is a fully absorbable intra-
oronary device comprised of semicrystalline poly(L-lactide)
(PLLA) coated with amorphous poly(D,L-lactide) (PDLLA)
copolymer that contains and controls the release of the
antiproliferative drug everolimus. Both polylactide materials
are completely degraded via hydrolysis. PLLA is biore-
sorbed via the Kreb’s energy cycle, and PDLLA is physio-
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1283logically processed via both Kreb’s cycle and methylglyoxal
metabolism (8,10,15). As previously shown, when this
process is imaged by IVUS, individual cross-sectional im-
ages show a diminishing gray-level intensity of the struts
over time (7).
Study procedure and imaging acquisition. All lesions were
reated with routine interventional techniques that included
andatory pre-dilation using a balloon shorter and 0.5 mm
maller in diameter than the study device. IVUS examina-
ions were performed at the different specified time points
post-implantation, 6-month, or 12-month follow-up) with
ither a phased-array 20-MHz IVUS catheter (EagleEye;
olcano Corporation, Rancho Cordova, California) or a
echanical rotating single-element catheter operating at 40
Hz (Atlantis, Boston Scientific, Natick, Massachusetts)
pplying an automated pullback speed of 0.5 mm/s (16).
otational, mechanical IVUS probes, operating at a fre-
uency of 40 MHz, rotate a single piezoelectric transducer
t 1,800 rpm, whereas electronic phased-array systems
perate at a center frequency of approximately 20 MHz.
igher ultrasound frequencies are associated with higher
mage resolution, but have decreased tissue penetration
apabilities (17). Electronic systems have up to 64 trans-
ucer elements in an annular array that are active sequen-
ially to generate the cross-sectional image (18). In general,
lectronic catheter designs are slightly easier to set up and
se, whereas mechanical probes offer superior image quality.
Quantitative IVUS analysis. To analyze and compare the
VUS data consistently, only IVUS examinations acquired
ith the same type of catheter and/or ultrasound consoles
20 or 40 MHz) at baseline and follow-up were included in
his study (19). Before quantitative IVUS was performed,
he IVUS data were retrospectively electrocardiogram-gated
y the previously validated Intelligate method (19,20). This
ethod selects fully automatic, near end-diastolic–acquired
VUS frames from a nongated IVUS study. Consequently,
his process allows for a smoother appearance of the
oronary vessel wall, which results in enhanced matching
etween baseline and follow-up studies, longitudinal con-
ouring, and echogenicity analysis (21,22). Of note is that a
ow frame rate (e.g., 10 frames/s instead of the optimal
etting of 30 frames/s) does not allow accurate detection of
ear end-diastolic frames and cannot be processed by the
ntelligate algorithm.
The post-procedural and follow-up IVUS images were
herefore analyzed side by side, comparing the matched
egments, as previously described (11). Only the treated
egments, identified by the first and the last cross sections
ontaining visible scaffold struts, were analyzed. The lumen,
caffold, and external elastic membrane contours were de-
ected using previously validated IVUS analysis software
CURAD Vessel Analysis, Curad BV. Wijk bij Duurstede,
he Netherlands) in longitudinal reconstructed views of the
oronary vessels (23). The contours of the analysis wereubsequently used to perform the echogenicity analysis of
he scaffolded segment.
Echogenicity analysis. Fully automated quantitative echo-
genicity analysis software, previously developed in-house
and validated, was used to quantify the hyperechogenicity
changes in the scaffolded segment (7,24). In brief, the
mean gray value of the adventitia was used to classify
tissue components as either hypo- or hyperechogenic.
The adventitia surrounding the coronary artery was
defined as a layer extending from 0.2 to 0.5 mm outside
the external elastic membrane. To avoid artifacts, tissue
within acoustic shadowed areas is excluded, and very high
gray-level pixels are identified as upper tissue (24). After
the tissue identification process, the relative fraction of
hypo- versus hyperechogenic tissue volumes was calcu-
lated for the entire scaffolded segment. At 6- and
12-month follow-up, the echogenicity was calculated
between the scaffold and the external elastic membrane
contours, as previously described (7). The software cal-
culated the echogenicity as a volume and percentage for
each scaffolded segment (setting hypoechogenicity and
hyperechogenicity to 100%).
The  hyperechogenicity was calculated for each scaf-
folded coronary segment, as follows:
% hyperechogenicity 6 months
% hyperechogenicity post ABSORB scaffold implantation
% hyperechogenicity post ABSORB scaffold implantation
 100%
The same formula was also applied to calculate the relative
change in hyperechogenicity at 12-month follow-up.
In a further analysis, the scaffold was subdivided into 3
segments of equal length (proximal, medial, and distal), and
the homogeneity of the hyperechogenicity changes at the
various pre-specified time points was investigated.
Statistical analysis. Categorical variables are expressed as
counts and percentages. Continuous variables are presented
as mean SD. The normal distribution of the variables was
nalyzed by the Kolmogorov-Smirnov test. IVUS-derived
arameters across all time points were compared with
arametric (paired sample t test) and nonparametric tests
(Wilcoxon test) for paired data, as appropriate, according to
their distribution. Correlation between plaque volume and
 hyperechogenicity was done by Spearman rank test, as
these variables were not normally distributed.
A 2-tailed value of p  0.05 was considered statistically
significant. Statistical analyses were performed with SPSS
16.0 software (SPSS Inc., Chicago, Illinois).
Results
Study patients. Overall, 37 and 54 patients underwent
paired IVUS imaging post-procedural and at 6- or
12-month follow-up in ABSORB Cohorts B1 and B2,
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1284respectively. For the purpose of the study, 9 and 19
patients were excluded from the Cohorts B1 and B2,
respectively, because different IVUS catheters (20 or 40
MHz) were used at baseline and/or follow-up (n  7) or
the quality of the pullbacks did not allow further post-
processing (n  21). Eventually, 63 patients (28 with
-month and 35 with 12-month follow-up) were in-
luded in the analysis (Table 1). No differences were
found between the patients included and those excluded
from the analysis in terms of baseline or angiographic
characteristics.
Table 2 shows the IVUS data for both cohorts. At 6
months, there was a small, significant reduction in mean
scaffold and lumen areas, whereas the mean vessel area
remained unchanged. At 12 months, no changes were found
in mean scaffold, lumen, and vessel areas.
Table 1. Clinical and Lesion Characteristics
C
Patient demographic and clinical data
Age, yrs
Male
Hypertension
Hypercholesterolemia
Diabetes
Current smoking
Prior PCI
Prior myocardial infarction
Stable angina
Unstable angina
Silent ischemia
Lesion and angiographic characteristics
Treated vessel
Left anterior descending artery
Left circumﬂex artery
Right coronary artery
ACC/AHA lesion type
Type A
Type B1
Type B2
Type C
QCA analysis pretreatment
Mean RVD, mm
MLD, mm
Diameter stenosis, %
Medical treatment
Beta-blockers
ACE inhibitors
Statins
Values are mean SD or n (%).
ACC/AHAAmericanCollegeofCardiology/AmericanHeartAssociatioPCI percutaneous coronary intervention; QCA quantitative coronary angQuantitative echogenicity analysis from post-implantation to
6 months. There was a nonsignificant increase of plaque
volume (Table 3). The % hyperechogenicity decreased
significantly between post-ABSORB implantation and the
6-month follow-up (p  0.001) (Fig. 1A). Overall, there
was on average a  hyperechogenicity of 15.51% (95%
confidence interval: 27.51 to 7.52).
There were no differences in  hyperechogenicity be-
tween proximal (4.22  35.57%), medial (10.7 
1.78%), and distal segments (10.80  45.41%; p 
.487) (Fig. 2A). No correlation was found between base-
ine plaque volume and  hyperechogenicity (Spearman rho 
.194, p  0.322).
Quantitative echogenicity analysis from post-implantation to
12 months. At 12 months, there was a nonsignificant
ncrease of plaque volume (Table 4). The % hyperechoge-
B1 (n  28) Cohort B2 (n  35)
.1 10.1 60.4 8.1
19 (68) 23 (66)
17 (61) 25 (74)
26 (93) 23 (66)
5 (18) 7 (20)
4 (14) 7 (20)
5 (18) 5 (14)
10 (36) 5 (15)
21 (75) 22 (63)
3 (11) 6 (17)
0 (0) 3 (9)
7 (25) 19 (53)
8 (29) 6 (17)
13 (46) 11 (31)
1 (4) 0
13 (46) 25 (71)
13 (46) 8 (23)
1 (4) 2 (6)
8 0.47 2.61 0.30
6 0.33 1.04 0.26
0 10.93 59.92 9.66
22 (80) 28 (82)
13 (47) 15 (44)
26 (96) 32 (94)
angiotensin-convertingenzyme;MLDminimum lumendiameter;ohort
62
2.6
1.0
60.1
n;ACEiography; RVD reference vessel diameter.
t
3
0
p
0
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1285nicity decreased significantly (p  0.001) (Fig. 1B). On
average, there was a  hyperechogenicity of 20.00% (95%
confidence interval: 27.32 to 12.00).
There were no differences in  hyperechogenicity be-
ween proximal (15.38  26.77%), medial (12.15 
0.32%), and distal segments (11.20  40.81%; p 
.920) (Fig. 2B). No correlation was found between baseline
laque volume and  hyperechogenicity (Spearman’s rho 
.101, p  0.564).
iscussion
The major findings of this study are: 1) the ABSORB
(1.1) demonstrates a smaller reduction in hyperechoge-
nicity during the first 6-month follow-up, as compared
with the first generation (1.0). This observation may be
representative of a slower degradation rate of the scaffold;
2) at 12 months, the relative reduction of hyperechoge-
nicity was slightly higher than that observed at 6 months;
and 3) the hyperechogenicity reduction was homoge-
neous over the length of the scaffold and did not correlate
with the underlying plaque volume.
Changes in material properties of polylactide have
previously been demonstrated to be measurable by
changes in the acoustic properties of the material over
time. Specifically, acoustic properties are influenced by
Table 2. IVUS Data From the Same Patients Used fo
Paired Patients (n  28) Post-Implantati
Mean lumen area 6.62 1.22
Mean vessel area 14.42 3.82
Mean scaffold area 6.60 1.16
Mean plaque area 7.80 2.87
Paired Patients (n  35)
Mean lumen area 6.27 1.02
Mean vessel area 14.24 3.48
Mean scaffold area 6.24 0.97
Mean plaque area 7.97 2.81
Values are mean SD.
IVUS intravascular ultrasound.
Table 3. Echogenicity Analysis Post-ABSORB Implan
Post-Implantation 6-M
Plaque volume, mm3 186.51 71.74 1
Calciﬁcation volume, mm3 0.11 0.21
Upper volume, mm3 2.38 4.79
Hyperechogenicity, mm3 38.91 20.19
Hyperechogenicity, % 22.58 9.77Values are mean SD.molecular weight, viscoelasticity, copolymer ratio, and
crystallinity changes in polylactide (25). Additionally,
Wu et al. (26), confirming that property changes of
biodegradable polymers can be detected by ultrasonic
waves, have further shown that the degradation behavior
of biodegradable polymers can potentially be monitored
through the application of ultrasonic techniques. In the
ABSORB Cohort A study, we demonstrated that quan-
titative differential echogenicity, as a method of deter-
mining the acoustic property changes of the ABSORB,
could be applied to monitor in vivo changes of the
scaffold (7,8). At the expected time of total degradation
and bioresorption (approximately 2 years), the acoustic
signals showed only little evidence of polymer residues
(7). Furthermore, histological studies in animal models at
2 to 4 years have demonstrated that the previous locations
of the struts were replaced by proteoglycans with occasional
microcalcification and ultimately by connective tissue (8,27).
Gel permeation chromatography confirmed that the molec-
ular weight of the PLLA was unquantifiable at 2 years after
implantation and that the polymer mass loss increases by
20%, 60%, and 90% at 1, 1.5, and 2 years, respectively,
becoming undetectable at 3 years (27).
In the present study, focusing on the first-year
follow-up after ABSORB bioresorbable vascular scaffold
chogenicity Analysis
6-Month Follow-Up p Value
6.35 1.11 0.007
14.70 3.74 0.161
6.42 1.09 0.004
8.35 2.83 0.002
12-Month Follow-Up
6.13 1.02 0.118
14.58 3.47 0.196
6.15 0.94 0.162
8.45 2.68 0.023
and at 6 Months (n  28)
ollow-Up
Relative Difference Based on
Individual Data, % p Value
69.50 12.67 32.98 0.127
0.22 15.75 51.24 0.520
2.07 57.50 79.61 0.001
16.26 6.65 26.29 0.094
6.69 15.01 28.68 0.001r the E
ontation
onth F
99.60
0.10
0.72
33.31
17.42
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1286(1.1) implantation, we demonstrated a smaller change in
 hyperechogenicity at 6 months as compared with its
first generation (1.0) (p  0.001) (Fig. 3). No difference
n baseline hyperechogenicity was present between Co-
orts B1 and B2 (22.58  9.77% vs. 23.51  8.57%, p 
.742). The accuracy of this method has been previously
eported (7,24). At 12 months, the  hyperechogenicity
f the ABSORB (1.1) was slightly higher when compared
ith 6 months. Although these data came from 2
ifferent groups of patients (Cohorts B1 and B2), a small
yperechogenicity reduction of ABSORB 1.1 could nev-
rtheless be extrapolated for the period between 6 and 12
onths, further supporting a low in vivo degradation rate
Figure 1. IVUS and Echogenicity Appearance of the Device Over Time
Intravascular ultrasound (IVUS) grey-scale images with the corresponding
IVUS images with hypo-echogenic (red) and hyperechogenic (green) areas
by quantitative echogenicity software presented as a color overlay, at 6 (A)
and 12 months (B). A reduced appearance of the hyperechogenic compo-
nent is visible at 6- and 12-month follow-up. BVS  bioresorbable vascular
scaffold.f the second-generation ABSORB scaffold. It is note-orthy that although in an animal model there was a
ignificant molecular weight degradation of ABSORB
ver the first 12 months (27), in humans, the small
hange in hyperechogenicity at 12 months may suggest
hat the microstructural features, which drive the hyper-
chogenicity signal of the scaffold, are retained for longer
imes post-implantation. Because the preservation of
emicrystalline microstructure is necessary for enduring
uminal support, this hypothesis is also consistent with
he observation of reduced scaffold area loss at 6 months
ith ABSORB (1.1) compared with its firs-generation
evice (9,14). Further studies are, however, required to
orrelate the ABSORB degradation process with the changes
n its mechanical properties (28).
In a further subanalysis, we also showed that the 
yperechogenicity is homogeneous over the entire length
f the scaffold and does not differ in relation to the
Figure 2. Echogenicity Changes Over the Length of the Scaffold
Changes in relative hyperechogenicity at 6 months (A) and at 12 months
(B), according to distal, medial, and proximal segments of the ABSORB
scaffold.
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1287volume of the baseline underlying plaque. We hypothe-
sized that  hyperechogenicity, used as a surrogate of the
ABSORB property changes, could not only be due to
intrinsic material property changes caused by degrada-
tion, but might also depend upon specific characteristics
of the scaffolded plaque, such as size and histochemical
characteristics (e.g., presence of macrophages) (29).
However, we found no correlation between plaque size and
change in hyperechogenicity at the various time points.
IVUS–virtual histology could be used to evaluate the
characteristics of the scaffolded plaque: the overestima-
tion of virtual histology– dense calcium and necrotic core
after ABSORB implantation precludes this kind of anal-
ysis (30,31).
It is of interest to note that although at 6 months there
was a significant reduction in mean scaffold area and in
mean lumen area, this was not observed at 12 months. This
phenomenon is supported by the fact that a constrictive
remodeling after balloon angioplasty, possibly inducing a
Table 4. Echogenicity Analysis Post-ABSORB Implan
Post-Implantation 12-M
Plaque volume, mm3 176.31 88.19 1
Calciﬁcation volume, mm3 0.12 0.21
Upper volume, mm3 2.00 3.00
Hyperechogenicity, mm3 39.06 20.24
Hyperechogenicity, % 23.51 8.57
Values are mean SD.
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Figure 3. Comparison in Terms of Echogenicity Changes Between ABSORBComparison between ABSORB 1.0 and 1.1 in terms of serial changes in hyperechogerestenotic process, ceased to be active after 4 months (32).
ypothetically then, at 12-month follow-up, it seems that
here are no elastic vessel forces active anymore on the
caffold, whose radial force has conversely partially subsided
s indicated by the vasoconstriction and vasodilatation
nduced by vasoactive drugs (33). Further follow-up at
uture time points (e.g., at 2 and 3 years) is required to
xtend the significance of the current findings.
Finally, our standardized software analysis method to
ssess the echogenicity of the scaffolded segment over time
epresents a clinically relevant tool for the bioresorbable
caffold era. This analysis approach may provide indirect
nformation on scaffold degradation, performance of these
evices in various types of lesions (calcified, fibrotic, eccen-
ric, degenerated vein graft) and a method to compare other
ypes of present and future bioresorbable scaffold platforms.
Study limitations. The main limitation of this observa-
ional study is the relatively small study population. To
aintain the highest quality for analysis, we had to
and 12 Months (n  35)
Follow-Up
Relative Difference Based on
Individual Data, % p Value
67.90 33.07 70.58 0.219
0.31 22.55 69.67 0.611
2.17 56.92 51.17 0.590
15.02 3.17 54.43 0.050
7.19 19.66 22.32 0.001
12 months 24 months
ABSORB 1.0
ABSORB 1.1 (Cohort B1)
ABSORB 1.1 (Cohort B2)
nd 1.1tation
onth
97.13
0.16
1.39
34.06
18.251.0 anicity. Mean values and standard errors are reported.
a
i
c
r
a
t
C
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1288exclude some patients for whom the data were acquired
with different ultrasound catheters or with a low frame
rate, making baseline and follow-up paired matching
unreliable (34). The use of 20-MHz IVUS catheters may
ffect the accurate detection of the scaffold as a result of
ts relatively low IVUS resolution (as compared with the
ommercially available 40-MHz catheters); conversely, a
elatively low resolution comes with a relatively high
coustic energy, which improves the sensitivity to pick up
he scaffold struts.
onclusions
The second-generation ABSORB scaffold (1.1) demon-
strated a reduced amount of change in ultrasound-derived
parameters (e.g., changes in hyperechogenicity) at 6 and 12
months (15% and 20%, respectively), compared with its
first generation (1.0). This observation may be representa-
tive of a slower degradation rate of the scaffold. Longer
follow-up is required to confirm these findings and their
clinical significance.
Reprint requests and correspondence: Dr. Nico Bruining, Tho-
raxcenter, Erasmus Medical Center, P.O. Box 1738, 3000 DR,
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